

**Electronic supplementary information**  
**Pyrido- and benzisothiazolones as inhibitors of histone**  
**acetyltransferases (HATs)**

S. D. Furdas,<sup>a</sup> I. Hoffmann,<sup>a</sup> D. Robaa,<sup>b</sup> B. Herquel,<sup>c</sup> W. Malinka,<sup>d</sup> P. Świątek,<sup>d</sup>  
A. Akhtar,<sup>c</sup> W. Sippl<sup>b</sup> and M. Jung<sup>a\*</sup>

<sup>a</sup> Institute of Pharmaceutical Sciences, Albert-Ludwigs-Universität Freiburg, Albertstraße 25,  
79104 Freiburg, Germany. E-Mail: manfred.jung@pharmazie.uni-freiburg.de


<sup>b</sup> Institute of Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Wolfgang-Langenbeck-  
Straße 4, 06120 Halle/Saale, Germany.

<sup>c</sup> Max Planck Institute of Immunobiology and Epigenetics, Stübeweg 51, 79108 Freiburg,  
Germany.

<sup>d</sup> Department of Chemistry of Drugs, Wrocław Medical University, Borowska 211, 50-556  
Wrocław, Poland.


**Figure S1: Compounds 1, 2, 3 and 4 inhibit hMOF *in vitro*.**

Side by side comparison with hMOF 200 ng and 5  $\mu$ M of each compound



Radioactivity (%)	1.74	100.00	40.31	47.37	47.72	43.42
St. error	0.00	21.83	9.77	3.60	16.42	3.45

**Figure S2: Inhibition of hMOF by compound 2 is dose dependent.**



Concentration	0	0.2 μM	0.5 μM	1 μM	2 μM	5 μM
Radioactivity (%)	100	100	78.7	64.7	39.5	37.9